Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...
Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive ...
CHICAGO — Topical antibiotic prophylaxis is completely unnecessary in association with intravitreal injections, according to findings from more than 15,000 injections by a single surgeon who presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback